The Prädifa Technology Division of Parker Hannifin, the global leader in the field of motion and control technology, has ...

Breakthrough study uses chromosome physical properties to monitor breast cancer therapy outcomes and predict recurrence ...

Positive preliminary data from the phase 1b/2 trial evaluating Olvi-Vec in small cell lung cancer have been announced.

Plant behavior may seem rather boring compared with the frenetic excesses of animals. Yet the lives of our vegetable friends, ...

Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All participants with disease control experienced ...

Patients receive a single cycle of Olvi-Vec treatment for three consecutive days and, 21 days after the last dose of Olvi-Vec, receive platinum chemotherapy plus etoposide until disease progression or ...